Prospective investors should know that this is just the beginning, as according to financial analysts, InnoCan’s stock surged due to the publication of its recent experimental trials. The exposure bolstered market confidence and now many notable experts are recommending the company as a “Strong Buy.”
Currently, Canadian-Israeli pharmaceuticals company InnoCan Pharma’s (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) stock value has increased over 350% since last year.
On the Canadian Securities Exchange, InnoCan finished with an $0.83 CAD closure from earlier this month’s $0.62 CAD. This jump marks a critical milestone for the promising enterprise which focuses on CBD-Loaded technologies.
Established in 2018, InnoCan Pharma is one of the world’s most promising pharmaceutical technology enterprises, specializing in Cannabidiol (CBD) loaded delivery platforms. The company, in partnership with some of Israel’s most prestigious institutions, examines the effect of exosomes and liposomes combined with CBD on damaged cells in the central nervous system (CNS), and developments innovative solutions accordingly.
InnoCan Pharma is managed by some of the pharmaceutical industry’s most experienced executives, including CEO and Co-Founder Iris Bincovich, Executive Chairman Ron Mayron (former CEO of Teva Israel (NYSE: TEVA)), and Yoram Drucker, a founder of Pluristem (NASDAQ: PSTI) and Brainstorm (NASDAQ: BCLI). Presently, InnoCan is open for investment on the Canadian Securities Exchange (CSE) as INNO, Germany’s Frankfurt Stock Exchange (FSE) as IP4, and New York’s OTC Ventures Exchange (OTC) as INNPF.
According to the InnoCan Management Team, the company’s advanced research capabilities stem from its imperative partnerships with two of Israel’s elite research institutions, including Ramot Lab of Tel Aviv University and The Hebrew University of Jerusalem.
The company’s recent experimental findings, which sent its stock price in an upward frenzy, were conducted earlier this month in collaboration with the Hebrew University of Jerusalem, led by Professor Chezy Barenholz, Head of the Membrane and Liposome Research Department. The study validated its experts’ assertions that oral ingestion of CBD is not as effective as direct injection of CBDs into the bloodstream.
During the peak of the coronavirus (COVID-19) crisis, the company launched several studies into restoring damaged lung cells caused by the engulfing pandemic. In coordination, researchers at InnoCan and Tel Aviv University invented a ground-breaking treatment against COVID-19 by utilizing CBD-loaded exosomes (“CLX”).
Since the beginning of 2021, InnoCan Pharma has initiated a comprehensive strategy to attract long-term and high-profile investments. In addition to the company’s research and development of smart delivery systems, it has also expanded into CBD-based cosmetic products, featuring creams, lotions, oils, serums, and more. Under the name SHIR in Europe and Synony in the United States, InnoCan’s presence is growing on a global level.
In the coming months, pharmaceutical experts expect InnoCan Pharma to further pursue experimental trials regarding its CBD-loaded technologies. With many investors convinced that InnoCan Pharma’s is on the right path, continued scientific ventures with fruitful results will only compound the young biotech start-up’s stock to new heights. Therefore, many financial analysts are already projecting the company’s market assets to progress steadily with strong potentials for longstanding appreciation.
This article Innocan Pharma gained 350% in value this year – Is it still a good time to buy? appeared first on BreezyScroll.
Read more on BreezyScroll.